US 11,865,161 B2
Prophylactic and nutraceutical therapy
Catharina Svanborg, Malmo (SE); Manoj Puthia, Lund (SE); and Chin Shing Ho, Lund (SE)
Assigned to Hamlet Pharma AB, Lund (SE)
Filed by HAMLET PHARMA AB, Lund (SE)
Filed on Apr. 19, 2019, as Appl. No. 16/389,451.
Application 16/389,451 is a division of application No. 14/419,519, granted, now 11,103,561, previously published as PCT/GB2013/052132, filed on Aug. 8, 2013.
Claims priority of application No. 1214234 (GB), filed on Aug. 9, 2012; and application No. 1214237 (GB), filed on Aug. 9, 2012.
Prior Publication US 2019/0282669 A1, Sep. 19, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/38 (2006.01); A61K 31/201 (2006.01); A61K 35/20 (2006.01); A23L 33/18 (2016.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01)
CPC A61K 38/38 (2013.01) [A23L 33/18 (2016.08); A61K 9/0095 (2013.01); A61K 31/201 (2013.01); A61K 35/20 (2013.01); A61K 47/12 (2013.01); A61P 35/00 (2018.01)] 11 Claims
 
1. A method for preventing formation of a colon cancer, wherein the method comprises administering to an individual that does not have colon cancer, a biologically active complex comprising:
(i) alpha-lactalbumin;
(ii) a variant of alpha-lactalbumin, wherein the variant comprises an alpha-domain and has at least 80% sequence identity to alpha-lactalbumin; or
(iii) a peptide of up to 50 amino acids and comprising an alpha-domain of alpha-lactalbumin; and
(iv) a fatty acid or a salt thereof.